Nuvectis Pharma Stock (NASDAQ:NVCT)


OwnershipFinancialsChart

Previous Close

$7.73

52W Range

$4.44 - $11.80

50D Avg

$8.55

200D Avg

$7.56

Market Cap

$162.55M

Avg Vol (3M)

$171.32K

Beta

-0.26

Div Yield

-

NVCT Company Profile


Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 04, 2022

Website

NVCT Performance


NVCT Financial Summary


Dec 24Dec 23Dec 22
Revenue--$149.00K
Operating Income-$-22.90M$-19.23M
Net Income$-19.00M$-22.26M$-18.79M
EBITDA-$-22.90M$-19.23M
Basic EPS$-1.11$-1.43$-1.48
Diluted EPS$-1.11$-1.43$-1.48

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
ANGHAnghami Inc.
HOURHour Loop, Inc.
NRSNNeuroSense Therapeutics Ltd.
CELCCelcuity Inc.
IMMXImmix Biopharma, Inc.
LRMRLarimar Therapeutics, Inc.
CNTACentessa Pharmaceuticals plc
IKNAIkena Oncology, Inc.
IMRXImmuneering Corporation